DrugBiological
Nadofaragene firadenovec clinical trials
Also written SCH 721015, INSTILADRIN and rAd-IFN.
- studies test it
- 13
- open now
- 5
- in phase 3
- 5
- first study started
- 2009
Keep track of what changes. Save the nadofaragene firadenovec studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
13 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
- Phase 3
- 5
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 6
Ferring Pharmaceuticals (5) · Abramson Cancer Center at Penn Medicine (2) · Ferring Ventures Limited (1) · FKD Therapies Oy (1) · M.D. Anderson Cancer Center (1) · University of Washington (1) · Memorial Sloan Kettering Cancer Center (1) · University of California, Davis (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses nadofaragene firadenovec is read from its arms, and is right about nine times in ten.
Testing it · 13
- Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerRecruitingPhase 3Ferring PharmaceuticalsNCT06510374Written as Nadofaragene Firadenovec
- Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA TrialNot yet recruitingPhase 2University of WashingtonNCT07332351Written as Nadofaragene Firadenovec
- Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal PelvisRecruitingPhase 1/2Ferring PharmaceuticalsNCT06668493Written as Nadofaragene Firadenovec
- A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)RecruitingPhase 3Memorial Sloan Kettering Cancer CenterNCT06929286Written as Nadofaragene Firadenovec
- TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic AdenocarcinomaRecruitingPhase 1University of California, DavisNCT07189195Written as TR-002
- Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)Active, not recruitingPhase 3Ferring PharmaceuticalsNCT05704244Written as FE 999326
- Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural MesotheliomaCompletedPhase 3Ferring Ventures LimitedNCT03710876Written as rAd-IFN
- A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.WithdrawnPhase 4Ferring PharmaceuticalsNCT06390111Written as nadofaragene firadenovec
- ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)CompletedPhase 3Ferring PharmaceuticalsNCT02773849Written as ADSTILADRIN
- Combination Gene Transfer and ChemotherapyCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01119664Written as SCH 721015
- Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder CancerCompletedPhase 2FKD Therapies OyNCT01687244Written as INSTILADRIN
- 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT01162785Written as SCH 721015
- Intrapleural Gene Transfer for Pleural MesotheliomaCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01212367Written as SCH 721015
Given in every arm · 2 — nadofaragene firadenovec is usual care beside what is tested
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder CancerRecruitingPhase 3Ferring PharmaceuticalsNCT06545955Written as Nadofaragene Firadenovec
- Gene Therapy for Pleural MalignanciesCompletedPhase 1University of PennsylvaniaNCT00299962Written as SCH 721015
Codes
What other systems call nadofaragene firadenovec · ClinicalTrials.gg INT002127
- MeSH (NLM) C000731690nadofaragene firadenovecOne source NLM
- UNII (FDA) 0OOS09O1FHNADOFARAGENE FIRADENOVECConfirmed FDA, NLM
- NCI Thesaurus C71011Nadofaragene FiradenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731690 | nadofaragene firadenovec | One source NLM |
| UNII (FDA) | 0OOS09O1FH | NADOFARAGENE FIRADENOVEC | Confirmed FDA, NLM |
| NCI Thesaurus | C71011 | Nadofaragene Firadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.